Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant COVID-19 vaccine (Sf9 cell)
- Development stage
- Unknown
- Lead developer
- WestVac Biopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The recombinant COVID-19 vaccine (Sf9 cell) is a protein subunit vaccine developed by WestVac Biopharma and Sichuan University's West China Medical Center. It utilizes the baculovirus expression vector system (BEVS) in *Spodoptera frugiperda* (Sf9) insect cells to produce the SARS-CoV-2 spike (S) protein. This platform allows for rapid, high-yield production of recombinant proteins. The vaccine is typically formulated with an aluminum-based adjuvant (aluminum hydroxide) to enhance immunogenicity. It was granted emergency use authorization in China in December 2022 and has been evaluated in clinical trials as both a primary vaccination series and a heterologous booster dose against various SARS-CoV-2 variants.
- Brand names
- CoviccineWeikexin
- Other names
- recombinant COVID-19 vaccine (Sf9 cell)Sf9 cell-expressed recombinant SARS-CoV-2 spike protein vaccineSf-9 cell-expressed recombinant SARS-CoV-2 spike protein vaccineSf 9 cell-expressed recombinant SARS-CoV-2 spike protein vaccine重组新型冠状病毒疫苗（Sf9细胞）
02
Targets
BCR (Immunoglobulin G B Cell Receptor)MHC II (Major histocompatibility complex class II receptor)SARS-CoV-2 spikeγδ TCR (T-cell receptor)
Beyond the preview
Go deeper on recombinant COVID-19 vaccine (Sf9 cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant COVID-19 vaccine (Sf9 cell).